(Reuters) – The judge who oversaw the bankruptcy of Purdue Pharma said on Monday that some members of the Sackler family who own the OxyContin manufacturer face a "significant risk" of liability and may be on the hook for "huge money" over claims that the company drive the opioid epidemic.
USA Bankruptcy Judge Robert Drain in White Plains, New York, made the remark during the closing argument in a trial on Purdue's proposed reorganization plan.
"I think there is a significant risk that Sacklers, or some of them, could be responsible for huge sums," the judge said, adding that "the question is where you draw the line. "against future opioid-related disputes.
Judge Drain did not explicitly state how he will govern but suggested that he found the deal sufficient.
More than 500,000 Americans have died from opioid overdoses since 1
Judge Drain told U.S. Assistant Attorney Lawrence Fogelman that it would be "bone-chilling" to reject billions. dollars from Sacklers just because it is not enough to solve the entire US opioid crisis.
The judge is expected to announce a formal decision on the deal this week.
The money would go to various entities and individuals with opioid claims, as well as government and local opioid reduction programs.
Critics of the settlement argue that the disclaimers are too large.
A lawyer Representatives of Washington and Oregon, who oppose the plan, told Judge Drain on Monday that approving the deal would be a "historic mistake."
would receive if they meet certain standards.
At the beginning of Monday's hearing, a lawyer for Sacklers said they had agreed to limit the disclosure notices to exclude family protection from non-opioid claims.
But the essence of the editions, which protect Sacklers from opioid-related disputes, remains intact.
During testimony last week, members of the Sackler family said they would not contribute if they did not receive the releases. Catalog